NEW YORK (January 18, 2022) – UNICEF has signed several long-term agreements (LTA) with suppliers for the procurement of the new antiviral medicine Molnupiravir.
UNICEF procurement of Molnupiravir is dependent on clinical recommendations, regulatory approvals and compliance with UNICEF quality assurance requirements. In December, the US Food and drug administration issued an emergency use authorization for the use of Molnupiravir in the treatment of COVID19 in certain patients. Molnupiravir is currently under assessment by WHO.
These agreements will help ensure that low and middle-income countries (LMICs) have timely access to novel COVID-19 therapies. UNICEF will continue to work with ACT-A (Access to COVID-19 Tools Accelerator) partners and industry to ensure supply availability, achieve affordable prices and capacity to meet country needs. Supply will also be available for ACT-A partners wishing to deploy Molnupiravir in countries.
UNICEF will work closely with other ACT-A partners such as WHO, the Global Fund and Unitaid to ensure an equitable access to supply for LMICs.
# # #
About UNICEF
The United Nations Children’s Fund (UNICEF) works in more than 190 countries and territories to pursue a more equitable world for every child. UNICEF has helped save more children’s lives than any other humanitarian organization, by providing health care and immunizations, safe water and sanitation, nutrition, education, emergency relief and more.
UNICEF USA advances the global mission of UNICEF by rallying the American public to support the world’s most vulnerable children. Together, we are working toward a world that upholds the rights of all children and helps every child thrive. For more information, visit www.unicefusa.org.
For more information please contact:
Erica Vogel, UNICEF USA, 212.922.2480, [email protected]